Abstract:Background: The CTSN (Cardiothoracic Surgical Trials Network) recently reported no difference in left ventricular end-systolic volume index or in survival at 2 years between patients with severe ischemic mitral regurgitation (MR) randomized to mitral valve repair or replacement. However, replacement provided more durable correction of MR and fewer cardiovascular readmissions. Yet, costeffectiveness outcomes have not been addressed. Methods and results: We conducted a cost-effectiveness analysis of the surgical treatment of ischemic MR based on the CTSN trial (n=126 for repair; n=125 for replacement). Patient-level data on readmissions, survival, qualityof- life, and US hospital costs were used to estimate costs and quality-adjusted life years per patient over the trial duration and a 10-year time horizon. We performed microsimulation for extrapolation of outcomes beyond the 2 years of trial data. Bootstrap and deterministic sensitivity analyses were done to address parameter uncertainty. In-hospital cost estimates were $78 216 for replacement versus $72 761 for repair (difference: $5455; 95% uncertainty interval [UI]: −7784–21 193) while 2-year costs were $97 427 versus $96 261 (difference: $1166; 95% UI: −16 253–17 172), respectively. Quality-adjusted life years at 2 years were 1.18 for replacement versus 1.23 for repair (difference: −0.05; 95% UI: −0.17 to 0.07). Over 5 and 10 years, the benefits of reduction in cardiovascular readmission rates with replacement increased, and survival minimally improved compared with repair. At 5 years, cumulative costs and quality-adjusted life years showed no difference on average, but by 10 years, there was a small, uncertain benefit for replacement: $118 023 versus $119 837 (difference: −$1814; 95% UI: −27 144 to 22 602) and qualityadjusted life years: 4.06 versus 3.97 (difference: 0.09; 95% UI: −0.87 to 1.08). After 10 years, the incremental cost-effectiveness of replacement continued to improve. Conclusions: Our cost-effectiveness analysis predicts potential savings in cost and gains in quality-adjusted survival at 10 years when mitral valve replacement is compared with repair for severe ischemic MR. These projected benefits, however, were small and subject to variability. Efforts to further delineate predictors of long-term outcomes in patients with severe ischemic MR are needed to optimize surgical decisions for individual patients, which should yield more cost-effective care. Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00807040.

Economic Analysis and Long-term Follow-up of Distant Referral for Degenerative Mitral Valve Repair

Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network

3-Year Outcomes for Degenerative Mitral Regurgitation Repair in a Medicare Population

Ischemic mitral regurgitation: To repair or replace? A single center experience

The MitraClip Asia-Pacific Registry: Differences in Outcomes Between Functional and Degenerative Mitral Regurgitation.

Mitral Valve Repair vs. Replacement by Different Etiologies ― A Nationwide Population-Based Cohort Study ―

Mitral Valve Repair or Replacement? Our "Road Map" for the Appropriate Strategy

A review regarding the article 'Comparative efficacy and safety of mitral valve repair versus mitral valve replacement in Rheumatic heart disease: A high-value care systematic review and meta-analysis.'

Mortality and resource utilization in surgical versus transcatheter repeat mitral valve replacement: A national analysis

Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: risk factors for early and mid-term mortality†

Mitral valve repair versus replacement in patients with ischemic mitral regurgitation

Surgery and Transcatheter Intervention for Degenerative Mitral Regurgitation in The United States

Systematic review and meta-analysis of mid-term survival, reoperation, and recurrent mitral regurgitation for robotic-assisted mitral valve repair

Comparison of Transcatheter Edge-to-Edge Mitral Valve Repair for Primary Mitral Regurgitation Outcomes to Hospital Volumes of Surgical Mitral Valve Repair

Contemporary Outcomes of Degenerative Mitral Valve Surgery in a Regional Tertiary Care Center

Clinical outcomes following surgical mitral valve repair or replacement in patients with rheumatic heart disease: a meta-analysis

Efficacy of Mitral Valve Repair As an Adjunct Procedure to Coronary Artery Bypass Grafting in Moderate Ischemic Mitral Regurgitation: A Meta-Analysis of Randomized Trials

Early and late Results after Surgical Mitral Valve Repair: A High-Volume Center Experience

Early and long-term outcomes of mitral valve repair in degenerative mitral regurgitation

Surgical Management of Severe Ischaemic Mitral Regurgitation

[Comparison of mid-to-long term outcomes between mitral valve repair and biological valve replacement in patients over 60 with rheumatic mitral valve disease based on a propensity score matching study]